Skip to content

Excellus BCBS

Does Excellus BCBS cover Zepbound?

Yes. Excellus BCBS covers Zepbound for weight loss with prior authorization if your BMI is 40 or higher, or 35 or higher with a related condition. Other policy requirements and your plan's benefits also apply.

Policy document

  • Employer and ACA Marketplace: Covered with requirements. See the qualification pathways below.

Earliest policy review June 5, 2026. How we verify · Check your exact plan

Full requirements: Zepbound for Weight Loss (2 plan types)

Applies to Employer and ACA Marketplace plans.

Covered with requirements

Qualification pathways

You can qualify through any one of these.

Adult weight loss — Class III obesity

All of:

  • Age ≥ 18 years
  • BMI ≥ 40 kg/m² (Class III obesity)
  • Enrolled in qualified comprehensive weight management program for ≥3 consecutive months
  • Documentation of trial and failure of Foundayo (or documented contraindication to Foundayo)
  • Not used in combination with any other GIP and/or GLP-1 receptor agonist
  • Not used in combination with other weight loss drugs (Rx, OTC, or herbal)
  • Coverage criteria apply to Zepbound pens only (vials and Kwikpens are not a covered benefit)

Adult weight loss — Class II obesity with comorbidity

All of:

  • Age ≥ 18 years
  • BMI 35–39.9 kg/m² (Class II obesity)
  • Enrolled in qualified comprehensive weight management program for ≥3 consecutive months
  • Documentation of trial and failure of Foundayo (or documented contraindication to Foundayo)
  • Not used in combination with any other GIP and/or GLP-1 receptor agonist
  • Not used in combination with other weight loss drugs (Rx, OTC, or herbal)
  • Coverage criteria apply to Zepbound pens only (vials and Kwikpens are not a covered benefit)

Plus any one of:

  • Cardiovascular Disease
  • Dyslipidemia (high LDL, TG, or low HDL)
  • Gallstones
  • Gynecological abnormalities
  • Hypercholesterolemia
  • Hypertension
  • Metabolic Syndrome
  • MAFLD
  • Pulmonary Hypoventilation
  • Obstructive Sleep Apnea
  • Stress Incontinence
  • Type 2 Diabetes
  • Weight-Bearing Joint Arthropathy

Documentation to bring

  • Baseline BMI and weight documentation
  • Height documentation
  • Documentation of current enrollment in qualified comprehensive weight management program for ≥3 consecutive months
  • Proof of current and prior participation in comprehensive weight management program (receipt or certificate and dietary/exercise logs)
  • Documentation of trial and failure of Foundayo OR documented contraindication to Foundayo
  • Progress notes documenting clinical status at time drug was originally initiated (weight, height, BMI, comorbid conditions)

Quantity limits

  • 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg — 2 mL (4 pens) per 28 days; Maximum 14 twenty-eight-day supplies OR 5 eighty-four-day supplies per 365 days; first 6 fills for new starts limited to 28-day supply or less; 2.5mg strength limited to 2mL per 365 days (titration only, not for chronic use beyond initial 4-week titration period) (84-day)

Approval and renewal

  • Initial approval: 7 months
  • Renewal: every 6 months
  • Renewal: At initial recertification (7 months): physician-verified weight loss of ≥5% of initial weight. For ongoing 6-month recertifications: must have maintained ≥5% weight loss OR continued to lose weight; current BMI must not be less than 18.5 kg/m². Patient must be utilizing maintenance dose (5mg, 7.5mg, 10mg, 12.5mg, or 15mg). For patients unable to tolerate approved maintenance doses, minimum of 5mg once weekly will be covered. Continued comprehensive weight management program enrollment required.
  • Renewal: At least 17 weeks on therapy before the first renewal.
  • Renewal: Staying on a maintenance dose of at least 5 mg.

Not covered when

  • Zepbound vials and Kwikpens are not a covered benefit (patients may obtain through LillyDirect access program)
  • Non-FDA approved diagnoses not covered
  • Combination with other GIP and/or GLP-1 receptor agonists not approved (Exenatide, Victoza, Ozempic, Rybelsus, Trulicity, Mounjaro)
  • Combination with any other weight loss drugs (Rx, OTC, or herbal) not approved
  • 2.5mg strength limited to initial 4-week titration only — not covered for chronic use
  • Organic causes of obesity (e.g., hypothyroidism) must be excluded before prescribing
  • Demonstration of failed efficacy (not meeting continuation criteria) precludes future coverage of same drug

Exceptions

  • New York: All utilization management requirements compliant with applicable New York State insurance laws and regulations

Policy note: BMI thresholds may be adjusted for Asian population on case-by-case basis (BMI ≥25 kg/m² suggests clinical obesity). Documentation must reflect clinical status at time drug was originally initiated. Patients not treated in past 4 months considered new to therapy. OSA indication is integrated into existing weight management criteria (see OSA entry). Annual GLP-1 day-supply limits apply cumulatively across all products. Off-label use (e.g., pre-diabetes extension of SURMOUNT-1) subject to weight management criteria if efficacy is not independent of weight loss.

verified June 5, 2026 · source: Weight Management Policy Pdf · View policy document (PDF)

Open on its own page →

Full requirements: Zepbound for Obstructive Sleep Apnea (OSA) (2 plan types)

Applies to Employer and ACA Marketplace plans.

Covered with requirements

Qualification pathways

You can qualify through any one of these.

OSA in adults with obesity — integrated into weight management criteria (Class III obesity)

All of:

  • Age ≥ 18 years
  • Diagnosis of moderate to severe obstructive sleep apnea
  • Obesity (BMI ≥ 40 kg/m²)
  • Enrolled in qualified comprehensive weight management program for ≥3 consecutive months
  • Documentation of trial and failure of Foundayo OR documented contraindication to Foundayo
  • Not used in combination with any other GIP and/or GLP-1 receptor agonist
  • Coverage criteria apply to Zepbound pens only (vials and Kwikpens not covered)

OSA in adults with obesity — integrated into weight management criteria (Class II obesity with OSA comorbidity)

All of:

  • Age ≥ 18 years
  • Diagnosis of moderate to severe obstructive sleep apnea
  • BMI 35–39.9 kg/m²
  • OSA as qualifying comorbidity
  • Enrolled in qualified comprehensive weight management program for ≥3 consecutive months
  • Documentation of trial and failure of Foundayo OR documented contraindication to Foundayo
  • Not used in combination with any other GIP and/or GLP-1 receptor agonist
  • Coverage criteria apply to Zepbound pens only (vials and Kwikpens not covered)

Documentation to bring

  • Baseline BMI and weight documentation
  • Documentation of moderate to severe obstructive sleep apnea diagnosis
  • Documentation of obesity (BMI ≥35 kg/m² with OSA as comorbidity, or BMI ≥40 kg/m²)
  • Documentation of current enrollment in qualified comprehensive weight management program for ≥3 consecutive months
  • Proof of participation in comprehensive weight management program (receipt or certificate and dietary/exercise logs)
  • Documentation of trial and failure of Foundayo OR documented contraindication to Foundayo

Quantity limits

  • 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg — 2 mL (4 pens) per 28 days; Maximum 14 twenty-eight-day supplies OR 5 eighty-four-day supplies per 365 days; first 6 fills for new starts limited to 28-day supply or less; 2.5mg strength limited to 2mL per 365 days (titration only) (84-day)

Approval and renewal

  • Initial approval: 7 months
  • Renewal: every 6 months
  • Renewal: OSA indication uses same continuation criteria as weight management: ≥5% weight loss by 7 months at initial recertification; maintained ≥5% weight loss or continued weight loss at ongoing 6-month recertifications; BMI not less than 18.5 kg/m²; maintenance dose (5mg, 7.5mg, 10mg, 12.5mg, or 15mg) required at recertification. OSA diagnosis not re-verified at continuation.
  • Renewal: At least 17 weeks on therapy before the first renewal.
  • Renewal: Staying on a maintenance dose of at least 5 mg.

Not covered when

  • Zepbound vials and Kwikpens are not a covered benefit for this indication
  • Combination with other GIP and/or GLP-1 receptor agonists not approved
  • Combination with any other weight loss drugs (Rx, OTC, or herbal) not approved
  • 2.5mg strength limited to initial 4-week titration only
  • Clinical efficacy in OSA determined to be inherently dependent on weight loss — OSA indication integrated into weight management criteria

Exceptions

  • New York: All utilization management requirements compliant with applicable New York State insurance laws and regulations

Policy note: FDA approved Zepbound for moderate to severe OSA in adults with obesity on December 20, 2024. Plan has integrated OSA indication into existing weight management criteria because clinical efficacy in OSA is determined to be inherently dependent on weight loss. No specific AHI threshold is stated — policy refers to 'moderate to severe OSA' consistent with FDA-approved indication. No PAP therapy trial requirement specified. OSA qualifies as a comorbidity for Class II obesity coverage threshold. AHI minimum not quantified in this policy document.

verified June 5, 2026 · source: Weight Management Policy Pdf · View policy document (PDF)

Open on its own page →

Questions people ask
Does Excellus BCBS cover Zepbound?
Yes. Excellus BCBS covers Zepbound for weight loss with prior authorization if your BMI is 40 or higher, or 35 or higher with a related condition. Other policy requirements and your plan's benefits also apply.
How long does a Zepbound approval last with Excellus BCBS?
Weight Loss — Applies to Employer and ACA Marketplace plans. Initial approval: 7 months. Renewal: every 6 months. Obstructive Sleep Apnea (OSA) — Applies to Employer and ACA Marketplace plans. Initial approval: 7 months. Renewal: every 6 months.
What does Excellus BCBS require to renew Zepbound?
Weight Loss — Applies to Employer and ACA Marketplace plans. At initial recertification (7 months): physician-verified weight loss of ≥5% of initial weight. For ongoing 6-month recertifications: must have maintained ≥5% weight loss OR continued to lose weight; current BMI must not be less than 18.5 kg/m². Patient must be utilizing maintenance dose (5mg, 7.5mg, 10mg, 12.5mg, or 15mg). For patients unable to tolerate approved maintenance doses, minimum of 5mg once weekly will be covered. Continued comprehensive weight management program enrollment required. At least 17 weeks on therapy before the first renewal. Staying on a maintenance dose of at least 5 mg. Obstructive Sleep Apnea (OSA) — Applies to Employer and ACA Marketplace plans. OSA indication uses same continuation criteria as weight management: ≥5% weight loss by 7 months at initial recertification; maintained ≥5% weight loss or continued weight loss at ongoing 6-month recertifications; BMI not less than 18.5 kg/m²; maintenance dose (5mg, 7.5mg, 10mg, 12.5mg, or 15mg) required at recertification. OSA diagnosis not re-verified at continuation. At least 17 weeks on therapy before the first renewal. Staying on a maintenance dose of at least 5 mg.
How current is this information?
The oldest review date among the policies on this page is June 5, 2026. Each policy's effective and verification dates appear with its requirements. Confirm current benefits with your plan.

Also under Excellus BCBS: Mounjaro, Ozempic, Wegovy

Zepbound under other plans: Elevance Health, Highmark, Molina Healthcare, BCBS Alabama, BCBS Arizona, BCBS Arkansas, BCBS Massachusetts, BCBS Michigan

All insurance plans · All medications

Summary of Excellus BCBS's written policy, not a guarantee of coverage. Plans vary by employer and benefit design.